异丙托溴铵联合辅舒酮治疗哮喘急性发作患儿的效果  

Effect of ipratropium bromide combined with flixotide on children with acute asthma exacerbation

作　　者：唐光群 万娟 刘建英 陈凤君 Tang Guang-qun;Wan Juan;Liu Jian-ying;Chen Feng-jun(Department of Pediatrics,Ziyang Central Hospital,Ziyang 641300,China)

机构地区：[1]资阳市中心医院儿科,资阳641300

出　　处：《中国药物应用与监测》2024年第2期153-156,共4页Chinese Journal of Drug Application and Monitoring

摘　　要：目的分析异丙托溴铵与辅舒酮联用治疗小儿哮喘急性期的临床效果。方法以2021年1月—2023年6月收治的128例哮喘急性发作患儿为此次试验对象,按照随机数字表法将入选患者分为两组,对照组65例患儿使用吸入用辅舒酮气雾剂进行治疗,观察组63例患儿则加用复方异丙托溴铵溶液雾化吸入治疗。比较两组患儿的症状评分、免疫功能、临床疗效以及不良反应发生情况。结果治疗后两组患儿的日间、晚间症状评分均较治疗前降低,且观察组[分别为(0.21±0.04)、(0.62±0.16)分]较对照组[分别为(0.30±0.08)、(0.69±0.15)分]降低幅度更大(P<0.05);与治疗前相比,治疗后两组IgM、IgG、IgA水平均升高,且观察组[分别为(5.92±1.41)、(10.42±1.73)、(7.28±0.84)g·L^(-1)]高于对照组[分别为(4.81±0.65)、(8.98±1.44)、(6.38±0.81)g·L^(-1)](P<0.05);与对照组总有效率84.62%(55/65)相比,观察组的96.83%(61/63)更高(P<0.05);在不良反应发生率方面,两组对比差异无统计学意义(P>0.05)。结论异丙托溴铵联合辅舒酮治疗哮喘急性发作患儿的治疗价值较高,有助于提高患儿机体免疫功能,有效提升预后效果,且不会增加不良反应。Objective To investigate the effect of ipratropium bromide combined with flixotide on children with acute asthma exacerbation.Methods A total of 128 children with acute asthma exacerbation admitted to our hospital from January 2021 to June 2023 were enrolled in this trial,and they were divided into two groups using random number table methods.The patients in the control group(n=65)were treated with flixotide inhalation,and thsoe in the observation group(n=63)with ipratropium bromide inhalation on the basis of treatment regime in the control.The TCM symptom score,immune function,clinical efficacy and occurrence of adverse reactions were compared between the 2 groups.Results After treatment,the daytime and evening symptom scores of the two groups were lower than those before treatment(P<0.05).They were(0.21±0.04)and(0.62±0.16)scores in the observation group,which were significantly lower than(0.30±0.08),and(0.69±0.15)scores in the control group(P<0.05).Compared with those before treatment,the levels of IgM,IgG and IgA in the two groups increased after treatment(P<0.05),and the three indexes were(5.92±1.41)g·L^(-1),(10.42±1.73)g·L^(-1)and(7.28±0.84)g·L^(-1)in the observation group,which were larger than those of(4.81±0.65)g·L^(-1),(8.98±1.44)g·L^(-1)and(6.38±0.81)g·L^(-1)in the control(P<0.05).The observation group reported a higher clinical efficacy rate than the control[96.83%(61/63)vs.84.62%(55/65),P<0.05].There was no statistical difference in adverse reaction rate between the two groups(P>0.05).Conclusion Application of ipratropium bromide combined with flixotide for children with acute asthma exacerbation can effectively improve immune function and prognosis and there is no major increase in incidence.

关 键 词：哮喘 急性发作 异丙托溴铵 辅舒酮 免疫功能 

分 类 号：R969[医药卫生—药理学]